|
|
| |
| Prevalence and risk factors of infections (excluding tuberculosis) in patients on biotherapy: RBSMR registry
Download PDF
|
Soumaya SAYOURI, Nessrine AKASBI, Imane EL MEZOUAR, Redouane ABOUQAL, Lahsen ACHEMLAL, Fadoua ALLALI, Rachid BAHIRI, Imane EL BOUCHTI, Abdellah EL MAGHRAOUI, Imad GHOZLANI, Hasna HASSIKOU, Ihsane HMAMOUCHI, Linda ICHCHOU, Ouafae MKINSI, Redouane NIAMANE,
|
Abstract:
Introduction: Biologics are used for the treatment of Rheumatoid arthritis (RA), spondylarthritis (SpA) and many other conditions. While the efficiency of biologics has been established, there are adverse effects, which are dominated by infections.Objectives: To assess the prevalence of infections (excluding tuberculosis) in patients with chronic inflammatory rheumatic diseases undergoing biotherapy and to identify infection's predicting factors. Materials and methods : A prospective observational study was carried out on the inclusion on patients followed for chronic inflammatory rheumatic diseases: patients SpA according to ASAS classification criteria 2010 and RA according to ACR/EULAR classification criteria 2009 who were under biotherapy included in the Moroccan RBSMR registry. All the characteristics have been compared between two groups: patients who developed an infection and patients who did not. Results : Among 419 patients, 194 patients had spondylarthritis and 225 had RA. For patients with spondylarthritis the infection rate was estimated at 8.6% (17 patients); they were dominated by urinary tract and respiratory infections. 14 patients (6.2%) with RA presented infections; they were dominated by the ENT sphere, respiratory and urinary tract infections. The data we gathered are consistent with those in the literature; no factors associated with the infection have been found. The bi-variate analysis did not reveal any statistically significant difference between the groups. Conclusion: The literature data suggests that patients with chronic inflammatory rheumatic diseases undergoing biotherapy present an infectious risk. Our study proves that it increases morbidity and mortality risk. In order to screen for infection associated factors, monitoring during follow-ups is required.
|
|
|
| | |